Clark Estates Inc. NY Invests $1.99 Million in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Clark Estates Inc. NY acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 60,000 shares of the company's stock, valued at approximately $1,991,000. Clark Estates Inc. NY owned 0.10% of Harmony Biosciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of HRMY. Financial Management Professionals Inc. acquired a new stake in Harmony Biosciences during the first quarter worth approximately $29,000. GF Fund Management CO. LTD. bought a new position in shares of Harmony Biosciences during the fourth quarter worth approximately $41,000. CWM LLC lifted its holdings in Harmony Biosciences by 34.8% during the 1st quarter. CWM LLC now owns 2,704 shares of the company's stock worth $90,000 after purchasing an additional 698 shares during the last quarter. GAMMA Investing LLC grew its holdings in Harmony Biosciences by 222.9% in the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company's stock valued at $97,000 after buying an additional 2,022 shares in the last quarter. Finally, Virtus Investment Advisers Inc. bought a new stake in shares of Harmony Biosciences in the fourth quarter valued at about $124,000. 86.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HRMY shares. Truist Financial began coverage on shares of Harmony Biosciences in a research report on Monday, July 21st. They set a "buy" rating and a $48.00 price target on the stock. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Oppenheimer assumed coverage on Harmony Biosciences in a research report on Monday, June 2nd. They set an "outperform" rating and a $61.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group started coverage on shares of Harmony Biosciences in a research report on Thursday, July 10th. They set a "neutral" rating and a $33.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $51.00.

Harmony Biosciences Price Performance

HRMY stock traded down $0.78 during trading on Friday, reaching $34.40. 726,870 shares of the company were exchanged, compared to its average volume of 569,685. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.67 and a quick ratio of 3.63. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 13.13, a P/E/G ratio of 0.48 and a beta of 0.84. The company has a 50-day moving average of $34.09 and a two-hundred day moving average of $33.98.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.19. The company had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 20.53% and a return on equity of 24.32%. The company's revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.67 earnings per share. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.